ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Leveraging Non-Radiative Transitions in Asphaltenes-Derived Carbon Dots for Cancer Photothermal Therapy.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Light-Activated Iron Oxide Nanoparticles in Cancer Treatment: Synergistic Roles in Photothermal and Photodynamic Therapy.Cancers · 2026Review
- Light-responsive nanotherapeutic carbon dots: a next generation tool for cancer phototherapy.Journal of the National Cancer Center · 2026Review
- Magnetic fluorescent carbon dots synthesized via one-pot approach for tumor photothermal therapy.iScience · 2026Article
- A dual-functional PEG-tyrosine hydrogel with photothermal effect and antioxidant capacity for cancer therapy and tissue regeneration.Regenerative biomaterials · 2026Article
- Multiple Application Strategies of Carbon Dots in Cancer Treatment: Mechanisms, Progress and Challenges.International journal of nanomedicine · 2026Review
- Harnessing light: Synthesis, mechanisms, and pre-clinical biomedical applications of stimuli-responsive multiscale composites.Materials today. Bio · 2025Review
- Current applications and future perspectives on rare-earth-based materials in stomatology.iScience · 2025Review
- Harnessing Lignin-Derived Carbon Dots for Enhanced NIR Photothermal Ablation of Melanoma Cells.ACS omega · 2025Article
- Leveraging Non-Radiative Transitions in Asphaltenes-Derived Carbon Dots for Cancer Photothermal Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Functional nanomaterials for enhanced tumor photothermal therapy - the mechanisms and applications.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cancer photothermal therapy leverages the capability of photothermal agents to convert light to heat for cancer cell ablation and necrosis. However, most conventional photothermal agents (Au, CuS, Pd, mesoporous silica nanoparticles, and indocyanine green dye) either face scalability challenges or photobleached upon prolonged irradiation which jeopardizes practical applications. Here, asphaltenes-derived carbon dots (ACDs, 5 nm) are rationally engineered as a low-cost and photostable photothermal agent with negligible in vivo cytotoxicity. The abundant water-solvating functional groups on the ACDs surface endows them with excellent water re-dispersibility that outperforms those of most commercial nanomaterials. Photothermal therapeutic property of the ACDs is mechanistically described by non-radiative transitions of excited electrons at 808 nm via internal conversions and vibrational relaxations. Consequently, the ACDs offer cancer photothermal therapy in mice within 15 days post-exposure to one-time near infrared irradiation. This pioneering study showcases the first utilization of asphaltenes-based materials for cancer therapy and is expected to arouse further utilization of such materials in various cancer theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.